NFE2L2 and glioblastoma: To test the selective enhancement of treatment effects using CET-CH-6, we treated U87-MG GBM cells expressing p53wt with two of Nrf2 activators (CET-CH-1 and CET-CH-2) and inhibitors with (CET-CH-5 and CET-CH-6), along with DOX.